Search clinical trials for: pembrolizumab

Total 2353 results

GI Innovation, Inc.
Merck Sharp & Dohme LLC

Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...

Korea, Republic of, United States
Chirag G. Patil
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

Glioblastoma Multiforme

United States
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Carcinoma, Hepatocellular | Colorectal Neoplasms | Esophageal Neoplasms | Endometrial Neoplasms | Pancreatic Ductal Adenocarcinoma | Biliary Tract Neoplasms

Israel, United States, Australia, Belgium, Chile, France, Korea, Republic of, Netherlands, Spain, New Zealand
April Salama, M.D.
Merck Sharp & Dohme LLC; Olatec Therapeutics LLC

Recruiting

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Melanoma

United States
Samsung Medical Center

Recruiting

Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases (PHOEBS)

Non-small Cell Lung Cancer

Korea, Republic of
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Non Small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center

Recruiting

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Mycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary Syndrome | Sézary | Advanced Mycosis Fungoides

United States
Eli Lilly and Company
Merck Sharp & Dohme LLC; Loxo Oncology, Inc.

Recruiting

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Biliary Tract Neoplasms

Canada, United States, Japan, Australia, France, Korea, Republic of
Yale University
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Melanoma | Renal Cell Carcinoma | Metastatic Melanoma | Brain Metastases | Pembrolizumab | Lenvatinib | PD1/PD-L1 Experienced

United States
Maastricht University Medical Center
Erasmus Medical Center; Jules Bordet Institute; Academisch Ziekenhuis Maastricht

Recruiting

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Unspecified Adult Solid Tumor, Protocol Specific

Netherlands, Belgium
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Metastatic Esophageal Squamous Cell Carcinoma

Argentina, Chile, United States, Canada, China, Costa Rica, Denmark, France, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Romania, Ukraine, Singapore, Ma... and more
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; United States Department of Defense

Recruiting

Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Yonsei University

Not yet recruiting

Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Breast Cancer

Korea, Republic of
Providence Health & Services
Providence Cancer Center, Earle A. Chiles Research Institute

Recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Platinum-Resistant Urothelial Carcinoma

United States
Prof. Dr. med. Christian Gratzke
Merck Sharp & Dohme LLC

Recruiting

SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy (Pembro-SRT)

Urologic Cancer | Biochemical Recurrence of Malignant Neoplasm of Prostate

Germany
Dana-Farber Cancer Institute
Celldex Therapeutics

Recruiting

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Melanoma | Metastatic Melanoma

United States
Fundacion para la Investigacion Biomedica del Hospital...

Recruiting

Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy

Lung Cancer

Spain
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme LLC

Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

Australia, Spain, United States, France, Hungary, New Zealand, Poland, Serbia, Canada, Romania
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
University College, London
JP Moulton Charitable Foundation

Recruiting

REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE)

Melanoma | Renal Cell Carcinoma

United Kingdom
Radboud University Medical Center
Dutch Society of Physicians for Pulmonology and Tuberculosis

Recruiting

Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC (DEDICATION-1)

NSCLC

Netherlands
Microbio Co Ltd

Recruiting

Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC

NSCLC Stage IV

Taiwan
Inge Marie Svane
Technical University of Denmark

Recruiting

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

Malignant Melanoma

Denmark
M.D. Anderson Cancer Center

Recruiting

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 and other conditions

United States
TME Pharma AG
Merck Sharp & Dohme LLC

Not yet recruiting

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (OPTIMUS)

Metastatic Pancreatic Cancer
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

Malignant Pleural Mesothelioma

United States
Mayo Clinic

Recruiting

Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Adenoid Cystic Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma

United States
NovoCure GmbH
Merck Sharp & Dohme LLC

Recruiting

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

Non-small Cell Lung Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
University Hospital, Brest

Recruiting

Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC (PREDICTION)

Advanced Non Small Cell Lung Cancer

France
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma

United States, Canada, United Kingdom, Japan, Australia, Argentina, Chile, Israel, Belgium
Medical University Innsbruck
Merck Sharp & Dohme LLC

Recruiting

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC (INNWOP1)

Non Small Cell Lung Cancer

Austria
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Merkel Cell Carcinoma | Neuroendocrine Carcinoma of the Skin | Trabecular Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Recruiting

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

Melanoma

United States
Georgetown University
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Cervical Cancer | Metastatic Cervical Cancer

United States
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Solid Tumor
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )

ESCC | Adjuvant Treatment | Lymph Node Positive | Pembrolizumab

China
M.D. Anderson Cancer Center

Recruiting

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Head Neck Cancer | Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

United States
Monopteros Therapeutics Inc.

Recruiting

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer

United States
Asylia Diagnostics BV

Recruiting

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Melanoma | Lung Cancer

Belgium
Mamta Parikh
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial Carcinoma

United States
Tufts Medical Center
Partner Therapeutics, Inc.

Recruiting

A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Advanced Lung Non-Small Cell Carcinoma | Non-Small Cell Carcinoma of Lung, TNM Stage 4

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
Bryan Schneider, MD
Pfizer; Genentech, Inc.; Indiana University; Foundation Medicine; Vera Bradley Foundation...

Recruiting

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)

Breast Cancer | Triple Negative Breast Cancer

United States
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Recruiting

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)

Neuroendocrine Tumors | Prostate Cancer Metastatic

United States
National Cancer Institute (NCI)

Recruiting

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Gastroesophageal Junction (GEJ) Cancers | Advanced HNSCC

United States
University of Cologne

Not yet recruiting

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma (Pembro-CORE)

Classical Hodgkin Lymphoma

Germany
Crescendo Biologics Ltd.

Recruiting

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA)

Advanced and/or Metastatic Solid Tumours

Spain, United Kingdom, Netherlands, United States

Search clinical trials for: pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations